Led with experience, backed by an eye for innovation

An experienced growth company leader, Sri joined Inscripta as President and CEO in October 2020. Prior to that, Sri was President of Penumbra (NYSE: PEN), a global healthcare company focused on innovative therapies. Sri joined Penumbra in 2015, serving as CFO and Head of Strategy until his promotion to President in 2019. Earlier in his career, he spent 16 years at J.P. Morgan serving as Head of Healthcare and co-Head of Technology Equity Capital Markets working with emerging, high-growth life science and technology companies. 

Sri currently serves on the Board of Directors of Nevro (NYSE: NVRO) and 10x Genomics (Nasdaq: TXG), where he is also Chair of the Audit Committee. He is on the Board of the non-profit Testing for America. 

He holds a B.S. from the Massachusetts Institute of Technology.

Ted is an accomplished executive and entrepreneur with more than 25 years of experience in therapeutics, diagnostics, and industrial synthetic biology. He co-founded Sestina and served as CTO, leading the development of new technologies combining ultra-high throughput measurement systems, high dimensional data generation and advanced computational tools. Prior to Sestina, he served in executive management/​leadership roles at iCarbonX, HealthTell, Vanquish Oncology (Founder), Tethys Biosciences, Lawrence Livermore National Laboratory, Invenux Pharmaceuticals (Founder) and NeXstar Pharmaceuticals. Ted joined Inscripta as CTO in 2022 as part of the Sestina Bio acquisition. 

Ted received his PhD in Organic Chemistry from The Scripps Research Institute and his BS degree in Chemistry from the California Polytechnic State University, San Luis Obispo (Summa Cum Laude).

Passionate entrepreneur and scientific contributor and with a track record of success in the fields of life science, biochemistry and synthetic biology. Leadership experience in early phase R&D, IP strategy, and commercial stage product development. Experience in establishing scientific direction and lab operations in early-phase companies Focused on developing fast, efficient and cost effective technologies to derisk commercialization of bio-enabled processes and products.

Two decades of experience and innovation at the intersections of mathematics, computation, statistics, and biology. Deep expertise with the theory and application of machine intelligence (particularly in complex, high dimensional settings) to drive the rapid optimization of biological systems.

An experienced R&D leader, Andrew joined Inscripta as Vice President, Synbio Products in December 2022 as part of the acquisition of Sestina Bio. At Sestina, Andrew established and managed the R&D effort, working with a talented team to develop a manufacturing-focused technical thesis and platform. Prior to that, Andrew spent a decade leading R&D efforts at Demetrix and Amyris. 

Andrew holds a PhD from Harvard Medical School, was a Jane Coffin Childs Postdoctoral Fellow, and has a BA from Pomona College.

A geneticist with a background in plant biology and computational biology, Nandini brings over 15 years of experience delivering innovative solutions using genome editing technologies. She joined Inscripta in 2019 as Senior Director and quickly advanced to Vice President of Applications Development, leading the charge to evaluate the Onyx platform in E. coli and S. cerevisiae.

Before joining Inscripta, Nandini lead the Disease Resistance Trait Discovery program at Corteva Agriscience. Prior to that she served in various positions at DuPont Pioneer, Genentech, the University of California, Berkeley, and Rockefeller University. 

Nandini holds a PhD in Plant Biology from Texas A&M University. 

An accomplished scientist with a background in structural and computational biology, Benjamin brings over 10 years of experience conceiving, developing and launching products in cell and gene therapy, and gene editing, markets. He joined Inscripta in 2022 as Head of Product before taking on the role of Vice President of Mammalian Biology and Product Management, where he provides strategic oversight into the microbial business unit while leading the companies development efforts in mammalian biology.

Before joining Inscripta, Benjamin lead the Genome Engineering and Modulation business unit at MilliporeSigma. Prior to that he has served in various leadership roles at Berkeley Lights, Inc, Agilent Technologies, and was a co-founder at Nanopore Diagnostics. 

Benjamin holds a PhD in Biology and Biomedical Sciences from Washington University in St. Louis and an MBA from Washington University’s Olin School of Business.

Dipnath brings over two decades of experience in conceptualizing and building commerce in synthetic biological products. Creating long-term partnerships in product and technology space is his passion.

Before joining Inscripta, Dipnath was the Head of Business and Alliances at Inscripta’s subsidiary Infinome BioSciences. Prior to that, he worked for 18 years in various positions at Codexis, Inc., the world’s leading custom enzymes company with his most recent function there being Head of Alliances and Product Management. 

Dipnath holds a bachelors in Biology, Master’s in biochemistry, and PhD in Microbiology.

Alex Hutcheson has over 20 years of sales leadership experience in emerging technology and life science markets. Prior to Inscripta, he spent 12 years at Pacific Biosciences, serving as Sr. Director of Sales for the Americas. He was part of the team that sold the world’s first single molecule, real-time sequencing instruments and helped grow the long read sequencing market through multiple new product launches. In addition to PacBio, Alex has a proven record of commercial success in roles at Genetix (acquired by Danaher), Biacore (acquired by GE Healthcare), and Beckman Coulter. 

Alex earned a bachelor’s degree in Molecular and Cell Biology with High Distinction from the University of California, Berkeley.

With almost 20 years experience in management, operations, marketing, and sports medicine, Carrie has a passion for helping others and keeping business operations moving effectively and efficiently. Prior to her experience at Inscripta, she has worked at Codexis and Notable Labs in Operations roles.

She holds a Masters of Science from University of Massachusetts, Amherst.

As a business-minded, strategic, and solutions-driven legal executive, Justin brings 20 years of experience in senior legal positions at healthcare, software, medical device manufacturing and biotechnology companies. Prior to joining Inscripta, Justin served as a General Counsel and Chief Compliance Officer at Omada Health, a digital healthcare company, where he led the legal, privacy, compliance and regulatory functions for over 7 years. Before joining Omada Health, Justin held leadership roles at Momentum Design Lab, Flex and MediciNova.

He holds a JD from the University of California, Hastings College of the Law, and a BA from University of California, San Diego. 

Mike joined Inscripta in July 2021 with a long record of successful tech sector financial management and reporting. A licensed CPA, Mike has successfully led four previous companies through the IPO filing process, including 10x Genomics in 2019. While at 10x Genomics, he was responsible for scaling the finance and accounting organization from pre-revenue to global manufacturing and sales operations. Mike brings a unique blend of controllership, budgeting, mergers and acquisitions, taxation and strategic finance experience having worked in environments ranging from early-stage private equity backed companies to Fortune 50 and Global 10 companies.